

# Myelodysplastic syndromes (MDS)

**Guide to the completion of the EBMT data collection form:  
MDS\_v2.2**

28 March 2025

**EBMT Registry**

EBMT Clinical Research & Registry Department



**Co-funded by  
the European Union**

*Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.*

## Table of Contents

Introduction	4
Myelodysplastic neoplasms (MDS)	4
Disease	4
Date of diagnosis	4
MDS transformed into Acute Leukaemia and treatment was done for Acute Leukaemia?	4
MDS classification at diagnosis (WHO 2022)	5
Therapy-related MDS	6
Is this a donor cell leukaemia?	6
IPSS-R	6
IPSS-M	7
Extended dataset	9
Assessments at diagnosis	9
Haematological values	9
Peripheral blood	9
Haemoglobin (g/dL)	9
Platelets (109/L)	9
White blood cells (109/L)	9
% blasts	9
% monocytes	9
% neutrophils	9
Bone marrow	10
% blasts	10
Precise blast count not available	10
Bone marrow investigation	10
Hypocellularity	10
Fibrosis	10
Chromosome analysis	10
Chromosome analysis done before HCT/CT/IST treatment	10
Output of analysis	11
What were the results?	11
Date of chromosome analysis	11
Chromosome analysis details	11
Transcribe the complete karyotype	11
Molecular marker analysis	11
Molecular markers analysis done before HCT/CT/IST treatment	11
Date of molecular marker analysis	12
Molecular marker analysis details	12
TP53 mutation type	12

Extended dataset	12
PREVIOUS THERAPIES(between diagnosis and HCT/CT)	12
Previous therapy lines before the HCT/CT:	12
Bibliography	13

## Introduction

Please make sure you have already checked the **Introduction to the EBMT Registry Completion Guidelines** document latest version available under *Manuals and Reference Documents* section on [EBMT website](#).

## Myelodysplastic neoplasms (MDS)

MDS is a heterogeneous group of clonal haematopoietic stem cell disorders characterised by ineffective, dysplastic haematopoiesis, peripheral cytopenia and a variable rate of progression to acute myelogenous leukaemia (AML).

This form must be completed for all patients whose primary disease for which the HCT/CT treatment is given is MDS. If the MDS has transformed to AML before the HCT/CT treatment, please complete both the MDS diagnosis form and the Acute Leukaemias diagnosis form.

If MDS originated from Fanconi Anaemia (FA) or Aplastic Anaemia (AA) and the patient received treatment for these diagnoses, please complete the Bone Marrow Failure Syndromes (BMF) incl. Aplastic Anaemia (AA) diagnosis form in addition to the MDS diagnosis form. If no treatment was given for FA or AA, please complete the Non-indication diagnosis form in addition to the MDS diagnosis form.

No data items should be left blank unless specifically stated in the definition.

### Disease

#### Date of diagnosis

Report the date of the first pathological diagnosis of the disease. This is the date when the sample was collected for examination or (in its absence) the date indicated by a physician within the patient's medical record.

#### MDS transformed into Acute Leukaemia and treatment was done for Acute Leukaemia?

MDS can progress through different phases (subclassifications) from the time of diagnosis to transplantation. One of these phases can be AML.

If the patient is being transplanted for AML that has transformed from MDS, select **Yes** and complete the Acute Leukaemias diagnosis form in addition to the current form. Otherwise, check the **No** option.

## MDS classification at diagnosis (WHO 2022)

Please see the tables 1,2 and 3 below for definitions of the MDS subclassifications according to WHO 2022 (1).

Classification	Blasts	Cytogenetics	Mutations
MDS with low blasts and isolated 5q deletion (MDS-5q)	<5% BM and <2% PB	5q deletion alone, or with 1 other abnormality other than monosomy 7 or 7q deletion	
MDS with low blasts and SF3B1 mutation <sup>a</sup> (MDS-SF3B1)	<5% BM and <2% PB	Absence of 5q deletion, monosomy 7, or complex karyotype	SF3B1
MDS with biallelic TP53 inactivation (MDS-biTP53)	<20% BM and PB	Usually complex	Two or more TP53 mutations, or 1 mutation with evidence of TP53 copy number loss or cnLOH

Table 1. MDS with defining genetic abnormalities (WHO 2022).

<sup>a</sup> Detection of  $\geq 15\%$  ring sideroblasts may substitute for SF3B1 mutation

Classification	Blasts
MDS with low blasts (MDS-LB)	<5% BM and <2% PB
MDS, hypoplastic <sup>a</sup> (MDS-h)	
MDS with increased blasts (MDS-IB1)	5–9% BM or 2–4% PB
MDS with increased blasts (MDS-IB2)	10– 19% BM or 5–19% PB or Auer rods
MDS with fibrosis (MDS-f)	5–19% BM; 2–19% PB

Table 2. MDS, morphologically defined (WHO 2022).

<sup>a</sup> By definition,  $\leq 25\%$  bone marrow cellularity, age adjusted

Classification	Blasts
Childhood MDS <sup>a</sup> with low blasts	<5% BM; <2% PB
Childhood MDS <sup>a</sup> with increased blasts	5–19% BM; 2–19% PB

Table 3. Childhood MDS (WHO 2022).

<sup>a</sup> A clonal haematopoietic stem cell neoplasm arising in children and adolescents (<18 years of age)

## Therapy-related MDS

Indicate if MDS developed due to medical treatment (therapeutic agents or radiation).

### Is this a donor cell leukaemia?

If therapy- related MDS is Yes, please indicate if it was a donor cell derived leukemia. If there was no prior transplant please select **Not applicable (no previous allo HCT)**. If it is not known whether or not it was a donor cell derived leukemia, select **unknown**.

## IPSS-R

The Revised International Prognostic Scoring System (IPSS-R) (2) consists of the following:

- Haemoglobin value
- Absolute Neutrophil Count (ANC)
- Platelet count
- Bone marrow blasts (%)
- Cytogenetic risk group

Please see tables 4, 5 and 6 how to calculate this score. There are online calculators available, one example is: <https://www.mds-foundation.org/ipss-r-calculator/>

Cytogenetic risk groups	Cytogenetic abnormalities
Very good	-Y, del(11q)
Good	Normal, del(5q), del(12p), del(20q), double including del(5q)
Intermediate	del(7q), +8, +19, i(17q), any other single or double independent clones

Poor	-7, inv(3)/t(3q)/del(3q), double including -7/del(7q), Complex: 3 abnormalities
Very poor	Complex: >3 abnormalities

Table 4. Cytogenetic risk groups.

Prognostic variable	0	0.5	1	1.5	2	3	4
Cytogenetics	Very Good		Good		Intermediate	Poor	Very Poor
BM Blast (%)	≤2		>2-<5%		5-10%	>10%	
Haemoglobin (g/dL)	≥10		8-<10	<8			
Platelets (10 <sup>9</sup> /L)	≥100	50-<100	<50				
ANC (10 <sup>9</sup> /L)	≥0.8	<0.8					

Table 5. IPSS-R points.

Risk category	Risk score
Very Low	≤1.5
Low	>1.5 – 3
Intermediate	>3 – 4.5
High	>4.5 – 6
Very High	>6

Table 6. IPSS-R risk categories.

## IPSS-M

The Molecular International Prognostic Scoring System (IPSS-M) (3) combines genomic risk factors with haematological and cytogenetic risk factors and consists of the following:

- Haemoglobin value
- Platelet count

- Bone marrow blasts
- IPSS-R cytogenetic risk groups (see IPSS-R section above, table 4)
- Molecular information on 31 genes (see table 7)

There are online calculators available, one example is: <https://mds-risk-model.com/>

Prognostic genes	Additional genes
ASXL1	BCOR
CBL	BCORL1
DNMT3A	CEBPA
ETV6	ETNK1
EZH2	GATA2
FLT3	GNB1
IDH2	IDH1
KRAS	NF1
MLL PTD	PHF6
NPM1	PPM1D
NRAS	PRPF8
RUNX1	PTPN11
SF3B15q/SF3B1 $\alpha$	SETBP1
SRSF2	STAG2
TP53 multihit	WT1
U2AF1	

Table 7. Molecular information for IPSS-M.

Risk category	Risk score
Very Low	$\leq -1.5$
Low	$> -1.5 - -0.5$
Moderate Low	$> -0.5 - 0$
Moderate High	$> 0 - 0.5$
High	$> 0.5 - 1.5$
Very High	$> 1.5$

Table 8. IPSS-M risk categories.



*Extended dataset*

## Assessments at diagnosis

## Haematological values

Report the values from the blood tests performed at diagnosis.

## Peripheral blood

## Haemoglobin (g/dL)

Report the haemoglobin in grams per deciliter (g/dL). If the haemoglobin was not tested, select **not evaluated**. If the value is not known, select **unknown**.

Platelets ( $10^9/L$ )

Report the platelets in  $10^9$  cells per litre ( $10^9/L$ ). If the platelets were not tested, select **not evaluated**. If the value is not known, select **unknown**.

White blood cells ( $10^9/L$ )

Report the white blood cells in  $10^9$  cells per litre ( $10^9/L$ ). If the white blood cells were not tested, select **not evaluated**. If the value is not known, select **unknown**.

## % blasts

Report the blasts as a percentage. If the blasts were not tested, select **not evaluated**. If the value is not known, select **unknown**.

## % monocytes

Report the monocytes as a percentage. If the monocytes were not tested, select **not evaluated**. If the value is not known, select **unknown**.

## % neutrophils

Report the neutrophils as a percentage. If the neutrophils were not tested, select **not evaluated**. If the value is not known, select **unknown**.

## Bone marrow

Report the findings of the bone marrow investigation at diagnosis.

### % blasts

Report the blasts as a percentage. If the blasts were not tested, select **not evaluated**. If the value is not known, select **unknown**.

### Precise blast count not available

If the precise blast count is not available, indicate whether it was **below or equal to 5%**, **above 5%**, **Not evaluated**, or **Unknown**.

### Bone marrow investigation

Report the findings of the bone marrow investigation at diagnosis.

### Hypocellularity

Indicate if there was hypocellularity at time of diagnosis. Hypocellularity means there were fewer haematopoietic cells in the bone marrow than usual. If this was not checked, select **not evaluated**. If it is not known if there was hypocellularity, select **unknown**.

### Fibrosis

Indicate if the bone marrow biopsy revealed any signs of fibrosis at time of diagnosis. If this was not investigated, select **not evaluated**. If it is not known if there was bone marrow fibrosis, select **unknown**.

## Chromosome analysis

### Chromosome analysis done before HCT/CT/IST treatment

In this section describe the results of all chromosome analyses (all methods including FISH) performed at/after diagnosis but before the HCT/CT/IST treatment. If there were multiple chromosome analysis tests done on different dates, the results can be registered separately along with the test date.

Indicate if chromosome analysis was done or not before the HCT/CT/IST treatment. Check **Unknown** if it is not known whether it was performed.

### Output of analysis

Indicate if the output of the chromosome analysis will be reported as **separate abnormalities** or as a **full karyotype**.

## What were the results?

**Normal** - the chromosome analysis has been performed and the results have been found normal

**Abnormal** - the chromosome analysis has been performed and abnormalities have been found. In addition, indicate the total number of different abnormalities present (**number of abnormalities present**).

**Failed** - the chromosome analysis was done but failed

## Date of chromosome analysis

Indicate the date of the chromosome analysis. Check **Unknown** if it is not known when it was performed.

## Chromosome analysis details

Indicate for each abnormality in the table whether it was **Absent, Present** or **Not evaluated**.

If a chromosome abnormality was checked, but not listed as an option in the table, select **Other** and specify the abnormality, marking whether it was **Absent** or **Present**.

## Transcribe the complete karyotype

If it is not possible to report the chromosome analysis results as per the abnormalities table please enter the complete karyotype. Describe all abnormalities according to the ISCN karyotype nomenclature. This notation includes the total number of chromosomes, the sex chromosomes, and any extra, missing or mutated autosomal chromosomes. For example, **47, XY, +18** indicates that the patient has 47 chromosomes, is a male, and has an extra autosomal chromosome 18.

## Molecular marker analysis

### Molecular markers analysis done before HCT/CT/IST treatment

In this section, describe the results of all molecular marker analyses (performed at/after diagnosis but before the HCT/CT/IST treatment). If there were multiple molecular marker analyses tests done on different dates, the results can be registered separately along with the test date.

Indicate if molecular marker analysis was done or not before the HCT/CT/IST treatment. Check **Unknown** if it is not known whether it was performed.

### Date of molecular marker analysis

Indicate the date of the molecular marker analysis. If there were multiple molecular tests done on different dates, the results can be registered separately along with the test date.

## Molecular marker analysis details

If molecular marker analysis was performed, indicate for each marker in the table whether it was **Absent**, **Present** or **Not evaluated**.

If a molecular marker was evaluated, but not listed as an option in the table, select **Other** and specify the marker, indicating whether it was **Absent** or **Present**.

### TP53 mutation type

If TP53 mutation is present, indicate the mutation type if known. A TP53 mutation is considered a multi hit if it fulfils one of the following criteria

- 2 or more distinct mutations of TP53 with a VAF of  $\geq 10\%$
- 1 mutation and 1 deletion involving the TP53 locus
- 1 mutation with VAF  $\geq 50\%$
- 1 mutation with complex karyotype

A TP53 mutation is considered single hit if either one of the following criteria is fulfilled:

- a single TP53 mutation with VAF  $< 50\%$
- loss of 17p13 involving TP53 locus without TP53 mutations

If the lab report does not specify the type, select **Unknown**.

#### *Extended dataset*

### PREVIOUS THERAPIES(between diagnosis and HCT/CT)

#### Previous therapy lines before the HCT/CT:

Indicate if the patient underwent any previous therapy lines related to MDS/MPN overlap syndromes before the HCT/CT/GT treatment. A treatment is considered a new line of therapy when switching to a different drug (or different combination of drugs) due to toxicity or for progression or relapse of the disease. If answered **Yes**, complete the "Treatment non-HCT/CT/GT/IST" form.

## Bibliography

1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *Leukemia*. 2022;36:1703–19. doi: 10.1038/s41375-022-01613-1.
2. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. *Blood*. 2012;120(12):2454-2465. doi:10.1182/blood-2012-03-420489.
3. Bernard E, Tuechler H, Greenberg Peter L, Hasserjian Robert P, Arango Ossa Juan E, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. *NEJM Evid* (2022) 1:EVIDoa2200008. doi: 10.1056/EVIDoa2200008